Ridaforolimus

Generic Name: Ridaforolimus

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₄NO_₁₄P

CAS Number: 572924-54-0

Unique Ingredient Identifier: 48Z35KB15K

Indication: Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Ridaforolimus
Drug: Dalotuzumab
Drug: Exemestane

First Posted Date: 2012-05-24

Last Posted Date: 2019-03-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 80

Registration Number: NCT01605396

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: dalotuzumab
Drug: ridaforolimus

First Posted Date: 2011-09-09

Last Posted Date: 2016-06-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 21

Registration Number: NCT01431547

A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: Ridaforolimus

First Posted Date: 2011-09-09

Last Posted Date: 2019-03-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 20

Registration Number: NCT01431534

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

Phase 1

Completed

Conditions: Cancer, Advanced

Interventions: Drug: ridaforolimus

First Posted Date: 2011-06-27

Last Posted Date: 2019-04-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 15

Registration Number: NCT01380184

Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma

Phase 1

Withdrawn

Conditions: Soft Tissue Sarcoma

Interventions: Drug: ridaforolimus

First Posted Date: 2011-02-15

Last Posted Date: 2012-07-12

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Registration Number: NCT01296659

Locations: 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: ridaforolimus
Drug: MK-2206
Drug: MK-0752

First Posted Date: 2011-02-14

Last Posted Date: 2015-08-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 65

Registration Number: NCT01295632

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Phase 1

Completed

Conditions: Endometrial Cancer
Ovarian Cancer

Interventions: Drug: Ridaforolimus
Drug: Paclitaxel
Drug: carboplatin

First Posted Date: 2010-12-08

Last Posted Date: 2017-08-30

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 24

Registration Number: NCT01256268

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1

Terminated

Conditions: Neoplasms Malignant

Interventions: Drug: dalotuzumab
Drug: MK-0752
Drug: MK-2206
Drug: ridaforolimus

First Posted Date: 2010-11-19

Last Posted Date: 2018-08-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 47

Registration Number: NCT01243762

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: ridaforolimus + dalotuzumab
Drug: exemestane
Drug: ridaforolimus
Drug: dalotuzumab

First Posted Date: 2010-11-04

Last Posted Date: 2017-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 115

Registration Number: NCT01234857

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Ridaforolimus + Dalotuzumab
Drug: Ridaforolimus
Drug: Dalotuzumab

First Posted Date: 2010-10-14

Last Posted Date: 2015-01-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 63

Registration Number: NCT01220570

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy